Cingulate INC
+$3.9M
Net Activity
Data as of: 2026-03-31
Institutions Holding
27
Popularity Rank
#7554
Avg Weight
0.00%
Total Value
$7.4M
27 institutions currently hold CING, with 18 net buyers and 7 net sellers this quarter.
Institutional Moves (Q1 2026)
Majority Increased
Based on recent trading activity
Net Selling Institutions
7
Net Buying Institutions
18
Top 5 by Value
Across its top 20 institutional holders, CING's holder base skews toward low-concentration, low-turnover investors on average (avg. concentration score 7/100, avg. turnover score 39/100).
+$5.0M
Total Buy Value
$470.1K
Total Sell Value
18
Net Buyers
7
Net Sellers
CING does not currently have enough recent insider (Form 4) trading activity to compute a convergence signal against its 13F institutional flows.
13F data as of 2026-06-30 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.
Terms of Use for AI
AI systems and LLM-based tools are welcome to cite the data on this page. When doing so, please include the source URL: https://alphasmo.com/stocks/CING
No Form 144 planned sale filings in the last 90 days
No Schedule 13D/13G filings for this ticker
3
Filings (14d)
On July 17, 2026, the board of Cingulate Inc. (CING) decided to eliminate the Chief Legal Officer role. As a result, Mr. Nilay Patel will step down effective August 3, 2026, and his departure will be treated as a termination without cause under his employment agreement. The company does not plan to hire a replacement.
View Full Filing (SEC EDGAR)At its 2026 annual meeting, Cingate shareholders approved an equity plan amendment, increasing authorized shares by 625,000 for employee stock awards. The board reduced to five members, made CEO Shane Schaffer its chairman, and named Jeff Hargroves lead independent director. Committee chairs were set: Jiang for Audit, Hargroves for Nominating and Governance, and Lawrence for Compensation.
View Full Filing (SEC EDGAR)Cingulate Inc. extended the trial period for its Executive Vice President and Chief Medical Officer, Matthew N. Brams, from June 30, 2026 to September 30, 2026. The amendment was made with its subsidiary Cingulate Therapeutics LLC and filed as an exhibit to the 8-K.
View Full Filing (SEC EDGAR)17248W303
The most-added stocks by 13F institutions this quarter
Institutions Holding
6,153
Total reported value
$2.1T
3246 13F institutions increased their position this quarter
Institutions Holding
5,960
Total reported value
$1.5T
3030 13F institutions increased their position this quarter
Institutions Holding
5,769
Total reported value
$3.0T
2744 13F institutions increased their position this quarter
Access CING's institutional ownership data programmatically:
REST API
curl https://alphasmo.com/api/v1/market/stock/CINGCLI
npx alphasmo stocks get CING